Use of multifunctional ligands for treating the respiratory distress and cytokine storm syndromes associated with coronavirus viral infections

Abstract

The enantiomers of AMINO-7 TRIETHOXY-4,5,6 OXO-1 DIHYDRO-1,3 ISOBENZOFURANNYL-3)-1 METHOXY-8 METHYL-2 METHYLENEDIOXY-6,7 TETRAHYDRO-, 2,3,4 ISOQUINOLINE or tritoqualine and deuterated derivatives thereof, capable of preventing and treating cytokine storm and respiratory distress in coronavirus infections.

1 - 5 . (canceled) 
     
     
         6 . A method of treating coronavirus infection-related cytokine storm in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of 7-Amino-4,5,6-triethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)phthalide and deuterated derivatives thereof. 
     
     
         7 . A method of preventing coronavirus infection-related cytokine storm in a subject, comprising administering to subject in need thereof a therapeutically effective amount of 7-Amino-4,5,6-triethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)phthalide and deuterated derivatives thereof. 
     
     
         8 . A method of treating a coronavirus infection-related respiratory distress in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of 7-Amino-4,5,6-triethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)phthalide and deuterated derivatives thereof. 
     
     
         9 . A method for preventing coronavirus infection-related respiratory distress in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of 7-Amino-4,5,6-triethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)phthalide and deuterated derivatives thereof. 
     
     
         10 . The method according to  claim 6 , wherein the 7-Amino-4,5,6-triethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)phthalide and deuterated derivatives thereof are packaged in the form of soft gelatin capsules, tablets, capsules, syrup or gel.